Joanna Zieliska, Anna Krupa-aska, Marek Kulus, Katarzyna Grzela Department of Paediatric Pulmonology and Allergology, Medical University of Warsaw, Warsaw, PolandThese authors contributed equally to this workCorrespondence: Katarzyna Grzela, Department of Paediatric Pulmonology and Allergology, Medical University of Warsaw, 63A Zwirki i Wigury Street, Warsaw, 02-091, Poland, Email katarzyna.grzela@wum.edu.plPurpose: To compare the efficacy and safety of two sesame protein maintenance doses (300 mg vs 1200 mg) in pediatric oral immunotherapy (OIT) for sesame allergy.Patients and Methods: In this randomized, single-center, open-label trial (NCT05158413), 26 children aged 4â 17 years with confirmed sesame allergy were allocated 1:1 to receive either 300 mg or 1200 mg sesame protein as maintenance therapy following dose escalation. Inclusion criteria included positive skin prick test (SPT) and/or elevated sesame-specific IgE (sIgE), as well as clinical reactivity during oral food challenge (OFC). The primary endpoint was the proportion of patients tolerating 4000 mg of sesame protein at the end-of-treatment OFC. Secondary outcomes included changes in immunologic markers (SPT wheal size, sIgE, IgG4) and safety.Results: The rate of negative OFCs in our study (81.8% in the high-dose group and 69.2% in the low-dose group; p = 0.649) was comparable to outcomes reported in previous sesame OIT trials (19â 22), indicating similar efficacy across different maintenance dose regimens. Both groups showed significant reductions in SPT wheal size and increases in sesame-specific IgG4 (pâ¯
ZieliÅska et al. (Thu,) studied this question.